Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA
{{output}}
Background: This studyevaluates the cost-effectiveness of sotorasib plus panitumumab in contrast to standardcare in the treatment of refractory colorectal cancer (CRC) with mutated KRASG12Cfrom the perspective of healthcare payer... ...
